Direct answer
A mechanistic and evidence-led review of tirzepatide as a dual GIP and GLP-1 receptor agonist, with guidance for laboratory assay design.
- Tirzepatide is one peptide with measurable activity at both GIP and GLP-1 receptors.
- Its receptor balance cannot be inferred from clinical outcomes alone and should be measured in matched assay systems.
- FDA and Health Canada authorization milestones occurred in 2022 for defined medicine products and uses.
What makes tirzepatide a dual agonist?
Tirzepatide is engineered to activate the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor. Dual agonism means that the same molecule engages both receptors, not that two separate peptides are mixed. The measured potency and efficacy depend on receptor expression, species, signalling readout and assay duration.
Because GIPR and GLP-1R are related class B GPCRs, a useful comparison requires matched cells, receptor density and analysis. Potency from one laboratory cannot be divided or multiplied against a result from a different platform without substantial uncertainty.
What did SURPASS-2 contribute?
SURPASS-2 compared three tirzepatide doses with semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. It measured glycemic and body-weight outcomes and reported gastrointestinal adverse events as the most common class. The study is important because it was an active-comparator trial rather than a cross-paper comparison.
It still does not isolate the mechanistic contribution of GIPR activation. Clinical outcomes integrate exposure, dose, adherence, receptor biology and population effects. Mechanistic attribution requires targeted experiments alongside the trial evidence.
When was tirzepatide authorized?
FDA lists Mounjaro among 2022 novel drug approvals and records May 13, 2022 as the original approval date. Health Canada records a Notice of Compliance dated November 24, 2022. These dates are useful anchors for historical articles, but the exact authorized indication and current label must be checked in the relevant jurisdiction.
An authorized tirzepatide medicine is not the same object as a research reagent. Laboratory materials must remain within legitimate research use and should not be represented as equivalent substitutes.
How should a dual-agonist assay be designed?
Run concentration-response curves at each receptor with a receptor-specific reference agonist, matched controls and sufficient replicates. Report potency, maximal response and curve quality. Confirm that the readout operates in a range where receptor reserve does not hide meaningful differences. If albumin is present, document its concentration because lipidated peptides can bind it.
Include a counterscreen for related receptors when selectivity is part of the claim. Verify material recovery at low concentration and consider adsorption to plastic. A nominal concentration is not necessarily the concentration available to the receptor.
What questions remain open for researchers?
Questions include how signalling bias varies by tissue, how receptor co-expression changes response, how chronic exposure affects desensitization and which receptor balance best predicts a particular endpoint. Those are experimental questions. They should not be answered by repeating a commercial description of dual agonism.
Continue through the evidence
Methods and quality. Receptor Bias and Potency in Incretin Peptide Research, How to Read a Peptide Certificate of Analysis, HPLC Peptide Purity: How to Read a Chromatogram Without Overclaiming, LC-MS for Peptide Identity: Molecular Mass, Charge States and Sequence Evidence and GLP-1 Receptor Assay Design: Controls, Curves and Interpretation.
Connected peptide briefings. Incretin Research: GLP-1, GIP and the Move to Multi-Receptor Agonists, Retatrutide: What Triple-Agonist Research Shows So Far, GIP Receptor Pharmacology: Why the Experimental Context Matters, Research Peptides in Canada: A Laboratory Procurement Guide, Health Canada, Peptides and Research Use Only: What the 2026 Guidance Means, Shipping and Storing Research Peptides Across Canada and Retatrutide, Tirzepatide and Semaglutide: How to Compare the Research.
Sources and further literature
- SURPASS-2: Tirzepatide versus semaglutide once weeklyPhase 3 randomized trial, New England Journal of Medicine, 2021.
- FDA novel drug approvals for 2022: MounjaroFDA records the May 2022 tirzepatide approval.
- Health Canada Notice of Compliance: MounjaroCanadian Notice of Compliance dated November 24, 2022.
North Specs separates scientific education from product claims. Review primary literature, current regulations and institutional requirements before designing laboratory work.
